Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopisk - andre dermatologiske præparater - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

amgen europe bv - sotorasib - carcinom, ikke-småcellet lunge - antineoplastiske midler - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

merck sharp & dohme b.v. - rocuroniumbromid - injektionsvæske, opløsning - 10 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

alternova a/s - hydroxocobalaminchloride - injektionsvæske, opløsning - 1 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - hydroxocobalaminchloride - injektionsvæske, opløsning - 1 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - dasatinib - filmovertrukne tabletter - 20 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

zentiva k.s. - dasatinib - filmovertrukne tabletter - 20 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirusinfektioner - antivirale midler til systemisk anvendelse - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). det bør overvejes at officielle vejledning om hensigtsmæssig brug af antivirale agenter.